Principal Investigator(s):Janine Maenza, Fred Hutchinson Cancer Research Center
Objective:To determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
Prevention Option(s):HIV Vaccine
Study Design:Non-randomized, Open label
Arms and Assigned Interventions
DescriptionParticipants will receive three injections of VRC-HIVDNA-016-00-VP at Months, 0, 1, and 2 and one injection of VRCHIVADV014-00-VP at Month 6.
Mode of DeliveryBiojector, Intramuscular
Official Code: NCT00955006
Trial Sponsors: NIAID
May 31, 2011
November 20, 2017
Age range: 18 Years ↔ 50 Years
Population:Cisgender Men, Cisgender Women